Fidelity Investments’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Fidelity Investments’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-12	Closed	-$350	–	5379
2024 Q1	$350	Buy	+12	New	+$329	﹤0.01%	4875
2019 Q1	–	Sell	-1	Closed	–	–	3601
2018 Q4	$0	Buy	+1	New	+$27	﹤0.01%	3516

Other funds holding BBC

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

DWS

Dynamic Wealth Strategies Granite Bay, California $173M AUM 14.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Fidelity Investments's BBC Position: Q2 2024 in Review

Fidelity Investments sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q2 2024, closing a stake of 12 shares — an estimated $350 sold.

Fidelity Investments first reported a position in BBC in Q4 2018 and held it in 2 quarters. The position peaked at $350 in Q1 2024. 14 funds tracked by Wall St. Rank hold BBC as of Q2 2024.

Fidelity Investments reported no remaining Virtus Biotech Clinical Trials ETF position as of Q2 2024 after selling out during the quarter.
Fidelity Investments sold 12 Virtus Biotech Clinical Trials ETF shares in Q2 2024, an estimated $350.
Fidelity Investments first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2018 and held it in 2 quarters.
Fidelity Investments's Virtus Biotech Clinical Trials ETF position peaked at $350 in Q1 2024.
14 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2024.

Based on Fidelity Investments's 13F filing for Q2 2024, filed 13 Aug 2024.